Early Detection of Alzheimers Disease Using Eye Imaging and Blood Biomarkers in Adults Aged 50 and Older

What this Trial Is About

Researchers are exploring ways to detect Alzheimers disease early by studying specific markers found in the blood and changes seen in eye imaging. This observational study focuses on adults aged 50 and older, including those diagnosed with Alzheimers, mild cognitive decline, subjective cognitive decline, or those with normal cognition. The goal is to identify plasma biomarkers and eye indicators that could help in early diagnosis of Alzheimers disease. Participants undergo detailed eye imaging using multimodal ophthalmic techniques and blood tests measuring plasma biomarkers such as A4240, p-tau181, p-tau217, NfL, and GFAP. These assessments are done at the beginning of the study to compare differences among various cognitive groups. The study observes these parameters to understand their relationship with the stages of Alzheimers disease. During the study, participants provide informed consent and undergo cognitive assessments alongside eye scans and blood sampling. Researchers measure differences in eye imaging parameters and plasma biomarker concentrations among groups at baseline. The trial is conducted under medical supervision by Peking University First Hospital and runs from March 2025 to August 2027, focusing on careful monitoring of diagnostic outcomes without administering treatments.

Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease